{"paper_id":"45eb3b47-daba-4c8d-bfd9-993a87316e82","body_text":"Published online by Cambridge University Press: 09 January 2023\nAlthough the role of myo-inositol (MYO) in promoting the oocyte quality of PCOS patients has been documented in human studies; the cellular effects of this supplement on oocytes have not been directly examined due to ethical limitations. In the first phase of this study, MYO dosimetry was carried out simultaneously with the PCOS model development. An effective dose was obtained following the assessment of fasting insulin and testosterone levels using ELISA and ovarian morphology appraisal by histopathology. In the second phase, following the continuous administration of the effective dose of MYO and dehydroepiandrosterone (DHEA), cellular evaluation was performed. The quality of oocytes from superovulation was analyzed by examining maturity and normal morphology percentage using a stereomicroscope, intracellular reactive oxygen species (ROS) and glutathione (GSH) levels using fluorometry, and ATP count evaluation using ELISA. The results revealed that, among the four different MYO concentrations, the 0.36 mg/g dose compared with the DHEA group reduced testosterone levels and large atretic antral follicles (LAtAnF) diameter. This dose also increased the corpus luteum count and the granulosa:theca (G/T)layer thickness ratio in antral follicles. Furthermore, this dose increased mature oocytes and normal morphology percentage, ATP count, and GSH levels; however, it decreased ROS levels in mature oocytes. Our findings provide the grounds for further cellular and molecular studies on the PCOS mouse model, suggesting that the improvement in mitochondrial function and its antioxidant properties is probably one of the mechanisms by which MYO increases oocyte quality.\n- Type\n- Research Article\n- Information\n- Copyright\n- © The Author(s), 2023. Published by Cambridge University Press\nAkbari Sene, A., Tabatabaie, A., Nikniaz, H., Alizadeh, A., Sheibani, K., Mortezapour Alisaraie, M., Tabatabaie, M., Ashrafi, M. and Amjadi, F. (2019). The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: A randomized clinical trial. Archives of Gynecology and Obstetrics, 299(6), 1701–1707. doi: 10.1007/s00404-019-05111-1\nCrossRefGoogle ScholarPubMed\nAmini, L., Tehranian, N., Movahedin, M., Ramezani Tehrani, F. R. and Soltanghoraee, H. (2016). Polycystic ovary morphology (PCOM) in estradiol valerate treated mouse model. International Journal of Women’s Health and Reproduction Sciences, 4(1), 13–17. doi: 10.15296/ijwhr.2016.04\nCrossRefGoogle Scholar\nAragno, M., Brignardello, E., Tamagno, E., Gatto, V., Danni, O. and Boccuzzi, G. (1997). Dehydroepiandrosterone administration prevents the oxidative damage induced by acute hyperglycemia in rats. Journal of Endocrinology, 155(2), 233–240. doi: 10.1677/joe.0.1550233\nCrossRefGoogle ScholarPubMed\nAragno, M., Mastrocola, R., Brignardello, E., Catalano, M., Robino, G., Manti, R., Parola, M., Danni, O. and Boccuzzi, G. (2002). Dehydroepiandrosterone modulates nuclear factor-κB activation in hippocampus of diabetic rats. Endocrinology, 143(9), 3250–3258. doi: 10.1210/en.2002-220182\nCrossRefGoogle ScholarPubMed\nArtini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M. and Cela, V. (2013). Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology, 29(4), 375–379. doi: 10.3109/09513590.2012.743020\nCrossRefGoogle ScholarPubMed\nAzhary, J. M. K., Harada, M., Takahashi, N., Nose, E., Kunitomi, C., Koike, H., Hirata, T., Hirota, Y., Koga, K., Wada-Hiraike, O., Fujii, T. and Osuga, Y. (2019). Endoplasmic reticulum stress activated by androgen enhances apoptosis of granulosa cells via induction of death receptor 5 in PCOS. Endocrinology, 160(1), 119–132. doi: 10.1210/en.2018-00675\nCrossRefGoogle ScholarPubMed\nBizzarri, M., Cucina, A., Dinicola, S., Harrath, A. H., Alwasel, S. H., Unfer, V. and Bevilacqua, A. (2016). Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? Medical Hypotheses, 91, 1–5. doi: 10.1016/j.mehy.2016.03.014\nCrossRefGoogle ScholarPubMed\nCardozo, E., Pavone, M. E. and Hirshfeld-Cytron, J. E. (2011). Metabolic syndrome and oocyte quality. Trends in Endocrinology and Metabolism, 22(3), 103–109. doi: 10.1016/j.tem.2010.12.002\nCrossRefGoogle ScholarPubMed\nChiu, T. T., Rogers, M. S., Law, E. L., Briton-Jones, C. M., Cheung, L. P. and Haines, C. J. (2002). Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: Relationship with oocyte quality. Human Reproduction, 17(6), 1591–1596. doi: 10.1093/humrep/17.6.1591\nCrossRefGoogle ScholarPubMed\nCiotta, L., Stracquadanio, M., Pagano, I., Carbonaro, A., Palumbo, M. and Gulino, F. (2011). Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: A double blind trial. European Review for Medical and Pharmacological Sciences, 15(5), 509–514.Google ScholarPubMed\nCroze, M. L., Vella, R. E., Pillon, N. J., Soula, H. A., Hadji, L., Guichardant, M. and Soulage, C. O. (2013). Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice. Journal of Nutritional Biochemistry, 24(2), 457–466. doi: 10.1016/j.jnutbio.2012.01.008\nCrossRefGoogle ScholarPubMed\nEini, F., Novin, M. G., Joharchi, K., Hosseini, A., Nazarian, H., Piryaei, A. and Bidadkosh, A. (2017). Intracytoplasmic oxidative stress reverses epigenetic modifications in polycystic ovary syndrome. Reproduction, Fertility, and Development, 29(12), 2313–2323. doi: 10.1071/RD16428\nCrossRefGoogle ScholarPubMed\nGenazzani, A. D., Prati, A., Santagni, S., Ricchieri, F., Chierchia, E., Rattighieri, E., Campedelli, A., Simoncini, T. and Artini, P. G. (2012). Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 28(12), 969–973. doi: 10.3109/09513590.2012.685205\nCrossRefGoogle ScholarPubMed\nGerli, S., Papaleo, E., Ferrari, A. and Di Renzo, G. C. (2007). Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences, 11(5), 347–354.Google ScholarPubMed\nGleicher, N., Weghofer, A. and Barad, D. H. (2011). The role of androgens in follicle maturation and ovulation induction: Friend or foe of infertility treatment? Reproductive Biology and Endocrinology: RBandE, 9(1), 116. doi: 10.1186/1477-7827-9-116\nCrossRefGoogle ScholarPubMed\nGoud, P. T., Goud, A. P., Van Oostveldt, P. and Dhont, M. (1999). Presence and dynamic redistribution of type I inositol 1, 4, 5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Molecular Human Reproduction, 5(5), 441–451. doi: 10.1093/molehr/5.5.441\nCrossRefGoogle ScholarPubMed\nHakimpour, S., Jelodar, G., Shabani, R., Pourheydar, B., Ajdary, M. and Mehdizadeh, M. (2022). Study of vitamin D3 formulation prepared by phytosolve technique and its effect on CTRP6 gene expression in PCOS model. Journal of Drug Delivery Science and Technology, 73, 103489. doi: 10.1016/j.jddst.2022.103489\nCrossRefGoogle Scholar\nHayes, M. G., Urbanek, M., Ehrmann, D. A., Armstrong, L. L., Lee, J. Y., Sisk, R., et al. (2015). Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nature Communications, 6, 7502. doi: 10.1038/ncomms8502\nCrossRefGoogle ScholarPubMed\nHenmi, H., Endo, T., Nagasawa, K., Hayashi, T., Chida, M., Akutagawa, N., Iwasaki, M., Kitajima, Y., Kiya, T., Nishikawa, A., Manase, K. and Kudo, R. (2001). Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biology of Reproduction, 64(1), 157–162. doi: 10.1095/biolreprod64.1.157\nGoogle ScholarPubMed\nHuang, Y., Yu, Y., Gao, J., Li, R., Zhang, C., Zhao, H., Zhao, Y. and Qiao, J. (2015). Impaired oocyte quality induced by dehydroepiandrosterone is partially rescued by metformin treatment. PLOS ONE, 10(3), e0122370. doi: 10.1371/journal.pone.0122370\nCrossRefGoogle ScholarPubMed\nIkeda, K., Baba, T., Morishita, M., Honnma, H., Endo, T., Kiya, T. and Saito, T. (2014). Long-term treatment with dehydroepiandrosterone may lead to follicular atresia through interaction with anti-Müllerian hormone. Journal of Ovarian Research, 7(1), 46. doi: 10.1186/1757-2215-7-46\nCrossRefGoogle ScholarPubMed\nKamenov, Z. and Gateva, A. (2020). Inositols in PCOS. Molecules, 25(23), 5566. doi: 10.3390/molecules25235566\nCrossRefGoogle ScholarPubMed\nKaruputhula, N. B., Chattopadhyay, R., Chakravarty, B. and Chaudhury, K. (2013). Oxidative status in granulosa cells of infertile women undergoing IVF. Systems Biology in Reproductive Medicine, 59(2), 91–98. doi: 10.3109/19396368.2012.743197\nCrossRefGoogle ScholarPubMed\nKim, H. H., Shaipanich, M., Hasselblatt, K. and Yeh, J. (2003). Induction of apoptosis and ovarian cyst formation in the mouse ovary by dehydroepiandrosterone (DHEA). Journal of Medicine, 34(1–6), 101–112.Google ScholarPubMed\nKockskämper, J., Zima, A. V., Roderick, H. L., Pieske, B., Blatter, L. A. and Bootman, M. D. (2008). Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 45(2), 128–147. doi: 10.1016/j.yjmcc.2008.05.014\nCrossRefGoogle ScholarPubMed\nKokosar, M., Benrick, A., Perfilyev, A., Fornes, R., Nilsson, E., Maliqueo, M., Behre, C. J., Sazonova, A., Ohlsson, C., Ling, C. and Stener-Victorin, E. (2016). Epigenetic and transcriptional alterations in human adipose tissue of polycystic ovary syndrome. Scientific Reports, 6, 22883. doi: 10.1038/srep22883\nCrossRefGoogle ScholarPubMed\nLaganà, A. S., Rossetti, P., Buscema, M., La Vignera, S., Condorelli, R. A., Gullo, G., Granese, R. and Triolo, O. (2016). Metabolism and ovarian function in PCOS women: A therapeutic approach with inositols. International Journal of Endocrinology, 2016, 6306410. doi: 10.1155/2016/6306410\nCrossRefGoogle ScholarPubMed\nLewin, L. M., Szeinberg, A. and Lepkifker, E. (1973). Gas chromatographic measurement of myo-inositol in human blood, cerebrospinal fluid and seminal fluid. Clinica Chimica Acta, 45(4), 361–368. doi: 10.1016/0009-8981(73)90036-3\nCrossRefGoogle Scholar\nMaurya, V. K., Sangappa, C., Kumar, V., Mahfooz, S., Singh, A., Rajender, S. and Jha, R. K. (2014). Expression and activity of Rac1 is negatively affected in the dehydroepiandrosterone induced polycystic ovary of mouse. Journal of Ovarian Research, 7(1), 32. doi: 10.1186/1757-2215-7-32\nCrossRefGoogle ScholarPubMed\nMehlmann, L. M. and Kline, D. (1994). Regulation of intracellular calcium in the mouse egg: Calcium release in response to sperm or inositol trisphosphate is enhanced after meiotic maturation. Biology of Reproduction, 51(6), 1088–1098. doi: 10.1095/biolreprod51.6.1088\nCrossRefGoogle ScholarPubMed\nMikaeili, S., Rashidi, B. H., Safa, M., Najafi, A., Sobhani, A., Asadi, E. and Abbasi, M. (2016). Altered FoxO3 expression and apoptosis in granulosa cells of women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics, 294(1), 185–192. doi: 10.1007/s00404-016-4068-z\nCrossRefGoogle ScholarPubMed\nNational Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. (2011). Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US). Available from: https://www.ncbi.nlm.nih.gov/books/NBK54050/ doi: 10.17226/12910\nGoogle Scholar\nNikmard, F., Hosseini, E., Bakhtiyari, M., Ashrafi, M., Amidi, F. and Aflatoonian, R. (2017). Effects of melatonin on oocyte maturation in PCOS mouse model. Animal Science Journal, 88(4), 586–592. doi: 10.1111/asj.12675\nCrossRefGoogle ScholarPubMed\nPapaleo, E., Molgora, M., Quaranta, L., Pellegrino, M. and De Michele, F. (2011). myo-inositol products in polycystic ovary syndrome (PCOS) treatment: Quality, labeling accuracy, and cost comparison. European Review for Medical and Pharmacological Sciences, 15(2), 165–174.Google ScholarPubMed\nPatel, S. S. and Carr, B. R. (2008). Oocyte quality in adult polycystic ovary syndrome. Seminars in Reproductive Medicine, 26(2), 196–203. doi: 10.1055/s-2008-1042958\nCrossRefGoogle ScholarPubMed\nQiao, J. and Feng, H. L. (2011). Extra- and intra-ovarian factors in polycystic ovary syndrome: Impact on oocyte maturation and embryo developmental competence. Human Reproduction Update, 17(1), 17–33. doi: 10.1093/humupd/dmq032\nCrossRefGoogle ScholarPubMed\nRavanos, K., Monastra, G., Pavlidou, T., Goudakou, M. and Prapas, N. (2017). Can high levels of d-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? European Review for Medical and Pharmacological Sciences, 21(23), 5491–5498. doi: 10.26355/eurrev_201712_13940\nGoogle ScholarPubMed\nSafiulina, D., Peet, N., Seppet, E., Zharkovsky, A. and Kaasik, A. (2006). Dehydroepiandrosterone inhibits complex I of the mitochondrial respiratory chain and is neurotoxic in vitro and in vivo at high concentrations. Toxicological Sciences, 93(2), 348–356. doi: 10.1093/toxsci/kfl064\nCrossRefGoogle ScholarPubMed\nSong, X., Shen, Q., Fan, L., Yu, Q., Jia, X., Sun, Y., Bai, W. and Kang, J. (2018). Dehydroepiandrosterone-induced activation of mTORC1 and inhibition of autophagy contribute to skeletal muscle insulin resistance in a mouse model of polycystic ovary syndrome. Oncotarget, 9(15), 11905–11921. doi: 10.18632/oncotarget.24190\nCrossRefGoogle Scholar\nTamura, H., Takasaki, A., Miwa, I., Taniguchi, K., Maekawa, R., Asada, H., Taketani, T., Matsuoka, A., Yamagata, Y., Shimamura, K., Morioka, H., Ishikawa, H., Reiter, R. J. and Sugino, N. (2008). Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. Journal of Pineal Research, 44(3), 280–287. doi: 10.1111/j.1600-079X.2007.00524.x\nCrossRefGoogle ScholarPubMed\nUbaldi, F. and Rienzi, L. (2008). Morphological selection of gametes. Placenta, 29, Suppl. B, 115–120. doi: 10.1016/j.placenta.2008.08.009\nCrossRefGoogle ScholarPubMed\nUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M. and Baillargeon, J. P. (2014). Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reproductive Sciences, 21(7), 854–858. doi: 10.1177/1933719113518985\nCrossRefGoogle ScholarPubMed\nUnfer, V., Dinicola, S., Laganà, A. S. and Bizzarri, M. (2020). Altered ovarian inositol ratios may account for pathological steroidogenesis in PCOS. International Journal of Molecular Sciences, 21(19), 7157. doi: 10.3390/ijms21197157\nCrossRefGoogle ScholarPubMed\nUnfer, V., Facchinetti, F., Orrù, B., Giordani, B. and Nestler, J. (2017). myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647–658. doi: 10.1530/EC-17-0243\nCrossRefGoogle ScholarPubMed\nUS Food and Drug Administration. (2005). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research (CDER), Rockville, MD. Available from: http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf.Google Scholar\nVitale, S. G., Rossetti, P., Corrado, F., Rapisarda, A. M. C., La Vignera, S., Condorelli, R. A., Valenti, G., Sapia, F., Laganà, A. S. and Buscema, M. (2016). How to achieve high-quality oocytes? The key role of myo-inositol and melatonin. International Journal of Endocrinology, 2016, 4987436. doi: 10.1155/2016/4987436\nCrossRefGoogle ScholarPubMed\nWang, F., Tian, X., Zhang, L., He, C., Ji, P., Li, Y., Tan, D. and Liu, G. (2014). Beneficial effect of resveratrol on bovine oocyte maturation and subsequent embryonic development after in vitro fertilization. Fertility and Sterility, 101(2), 577–586. e571. doi: 10.1016/j.fertnstert.2013.10.041\nCrossRefGoogle ScholarPubMed\nWesson, D. E. and Elliott, S. J. (1995). The H2O2-generating enzyme, xanthine oxidase, decreases luminal Ca2+ content of the IP3-sensitive Ca2+ store in vascular endothelial cells. Microcirculation 2(2), 195–203.CrossRefGoogle ScholarPubMed\nZacchè, M. M., Caputo, L., Filippis, S., Zacchè, G., Dindelli, M. and Ferrari, A. (2009). Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecological Endocrinology, 25(8), 508–513. doi: 10.1080/09513590903015544\nCrossRefGoogle ScholarPubMed\nZeng, L. and Yang, K. (2018). Effectiveness of myoinositol for polycystic ovary syndrome: A systematic review and meta-analysis. Endocrine, 59(1), 30–38. doi: 10.1007/s12020-017-1442-y\nCrossRefGoogle ScholarPubMed\nZhang, J., Bao, Y., Zhou, X. and Zheng, L. (2019). Polycystic ovary syndrome and mitochondrial dysfunction. Reproductive Biology and Endocrinology: RBandE, 17(1), 67. doi: 10.1186/s12958-019-0509-4\nCrossRefGoogle ScholarPubMed\nZhu, J. Q., Zhu, L., Liang, X. W., Xing, F. Q., Schatten, H. and Sun, Q. Y. (2010). Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Molecular Human Reproduction, 16(4), 260–266. doi: 10.1093/molehr/gap089\nCrossRefGoogle ScholarPubMed\nZimmermann, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain, 16(2), 109–110. doi: 10.1016/0304-3959(83)90201-4\nCrossRefGoogle ScholarPubMed\n- 10\n- Cited by\nCited by\nCrossref Citations\nGuo, Zhenhua\nLv, Lei\nLiu, Di\nMa, Hong\nand\nRadovic, Cedomir\n2023.\nA meta-analysis: Effect of androgens on reproduction in sows.\nFrontiers in Endocrinology,\nVol. 14,\nIssue. ,\nKhoshvaghti, Ameneh\nand\nRahbari, Raha\n2024.\nThe effect of ellagic acid on sex hormones and miRNA-21 expression in rats with polycystic ovary syndrome.\nNaunyn-Schmiedeberg's Archives of Pharmacology,\nVol. 397,\nIssue. 6,\np.\n4263.\nAnderson, George\n2024.\nPolycystic Ovary Syndrome Pathophysiology: Integrating Systemic, CNS and Circadian Processes.\nFrontiers in Bioscience-Landmark,\nVol. 29,\nIssue. 1,\nAlbadri, Haider M Badea\nAlrubaye, Yasir Sj\nand\nAbdulamir, Haidar A\n2025.\nInositol role in polycystic ovary syndrome (PCOS) and the awareness of Iraqi doctors regarding this role.\nJournal of Research in Pharmacy,\nVol. 29,\nIssue. 5,\np.\n1972.\nCheng, Xin\nMa, Dan\nWang, Xiuhong\nLi, Meiling\nand\nJiang, Jinpeng\n2025.\nCausal analysis of dietary preferences and the risk of endometriosis using large-scale population data.\nScientific Reports,\nVol. 15,\nIssue. 1,\nZhao, Yifan\nZhang, Gaochen\nPan, Jiexue\nand\nHuang, Hefeng\n2025.\nOne-carbon metabolism and risk of PCOS: insights from Mendelian randomization.\nJournal of Ovarian Research,\nVol. 18,\nIssue. 1,\nYang, Han\nXu, Chunyue\nLai, Lanfeng\nLuo, Bingyi\nZhang, Wenwen\nand\nYi, Wei\n2025.\nReconsidering antral follicle changes in the DHEA-induced PCOS model: the overlooked role of AMH and methodological variability.\nJournal of Ovarian Research,\nVol. 18,\nIssue. 1,\nZhang, Yanli\nShi, Baichao\nTian, Yuan\nXu, Shujun\nand\nChang, Hui\n2026.\nNutrients and bioactive compounds in polycystic ovary syndrome: updated insights into effects and underlying mechanisms.\nFrontiers in Nutrition,\nVol. 13,\nIssue. ,\nSubakathulla, Sumayyah\nManoj, Norwin\nPatanwala, Azima Muzzammil\nPremvignesh, Prasanna Appiya\nMaher Alobaid, Yamen\nMajie, Ankit\nGorain, Bapi\nDutta, Sulagna\nSengupta, Pallav\nRosas, Israel Maldonado\nand\nRoychoudhury, Shubhadeep\n2026.\nRedox-endocrine triad in PCOS: can vitamin D, myo-inositol, and melatonin synergize as bioactive cocktails?.\nFrontiers in Endocrinology,\nVol. 17,\nIssue. ,\nWei, Yaochang\nYang, Yifan\nLi, Yifan\nWang, Zhuangsheng\nDeng, Tingting\nHu, Xiaojiao\nJiang, Xuefeng\nXiao, Rui\nWu, Yanfang\nQing, Suzhu\nand\nWang, Yongsheng\n2026.\nFolic acid alleviates heat stress-induced ovarian dysfunction in dairy cows via modulation of follicular fluid metabolism and ABC transporter activity.\nAnimal Reproduction Science,\nVol. 292,\nIssue. ,\np.\n108240.","source_license":"public-domain-us","license_restricted":false}